Two ways to give chemotherapy into spinal fluid, compared
Original title: Comparison of intracerebrospinal fluid methotrexate by Ommaya reservoir versus lumbar puncture in leptomeningeal carcinomatosis with hydrocephalus: a retrospective cohort study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Doctors looked back at records of people already treated, so it shows what happened but does not prove one method is better.
The short version
In a small look back at past records, a small implanted port delivered chemotherapy into the spinal fluid with better symptom relief than repeated spinal taps, but people did not live longer.
What was studied. Doctors reviewed the records of 36 people whose cancer had spread to the lining of the brain and spinal cord, along with a buildup of fluid in the brain. All of them got the chemotherapy drug methotrexate into their spinal fluid. 15 got it through an Ommaya reservoir, a small port placed under the scalp, and 21 got it through a lumbar puncture, a needle in the lower back.
What they found. The overall response rate was 86.7% with the port and 47.6% with the spinal tap. The clinical response rate was 100% with the port and 52.4% with the spinal tap. The port also gave better relief of pressure inside the head. Side effects and complications were similar in both groups. How long people lived was not different between the two groups.
What this means, and what it doesn't
What it could mean: For people in this situation, the port may control symptoms and pressure in the head better than repeated spinal taps, without adding side effects. It did not help people live longer. The study also found that people whose cancer had spread outside the brain and spine had a higher risk of dying. People who were also getting targeted therapy lived longer.
What it doesn't mean: This is not a new treatment, and it is not a cure. Both methods are already used. This study looked back at records of people who had already been treated, so no one was randomly assigned to a group. That means the two groups may have differed in ways the study could not account for. It was also small, only 36 people at all. It does not prove that one method is better. It is not a promise that this will help any one person live longer.
Source: PubMed, July 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.